Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Want to see SLNO full AI Analyst Report?
Top Page
Soleno Therapeutics
(NASDAQ:SLNO)
Select Model
Select Model
Rating:81Outperform
Price Target:
$61.00
▲(15.57% Upside)
Action:ReiteratedDate:05/09/26
The score is driven primarily by strong TTM financial performance (rapid revenue growth, high margins, and strong free cash flow with very low leverage). Earnings-call commentary supports continued commercial momentum, though it flags meaningful execution risks (COGS normalization, gross-to-net/seasonality, and discontinuation). Technicals are positive but appear overbought, and valuation is reasonable on P/E with no dividend yield support.
Positive Factors
Strong cash generation & low leverage
The company generated substantial operating and free cash flow on a large TTM revenue base while carrying almost no debt. That durable cash generation and conservative leverage provide financing flexibility to fund commercialization, R&D and potential strategic moves over the next several quarters without urgent external capital.
Negative Factors
Limited historical revenue track record
The sharp inflection to profitability and revenue is recent, with prior periods showing no revenue and large losses. That limited multi‑year track record increases uncertainty about the persistence of current margins and growth, making future performance sensitive to execution, seasonality and single‑product concentration.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation & low leverage
The company generated substantial operating and free cash flow on a large TTM revenue base while carrying almost no debt. That durable cash generation and conservative leverage provide financing flexibility to fund commercialization, R&D and potential strategic moves over the next several quarters without urgent external capital.
Read all positive factors
Soleno Therapeutics (SLNO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.76B
Dividend YieldN/A
Average Volume (3M)5.18M
Price to Earnings (P/E)13.9
Beta (1Y)0.91
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,120,148
10 Day Avg. Volume12,027,162
30 Day Avg. Volume5,177,705
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)5.47
Price to Sales (P/S)12.93
P/FCF Ratio52.69
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue9.23
Enterprise Value/Gross Profit14.02
Enterprise Value/Ebitda25.90
Forecast
1Y Price Target
$61.00Price Target Upside15.57% Upside
Rating ConsensusHold
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Soleno Therapeutics Business Overview & Revenue Model
Company Description
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-da...
How the Company Makes Money
Soleno primarily makes money by selling its prescription pharmaceutical product, VYKAT XR (diazoxide choline) extended‑release tablets, in the United States. Revenue is generated through product sales to customers in the pharmaceutical distributio...
Soleno Therapeutics Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 285.01M | 190.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 187.70M | 187.71M | 0.00 | -1.96M | 0.00 | 0.00 |
| EBITDA | 101.57M | 28.38M | -173.63M | -37.03M | -22.10M | -30.30M |
| Net Income | 96.04M | 20.89M | -175.85M | -38.99M | -24.07M | -30.91M |
Balance Sheet | ||||||
| Total Assets | 608.39M | 563.83M | 330.97M | 180.69M | 26.50M | 35.55M |
| Cash, Cash Equivalents and Short-Term Investments | 255.60M | 305.47M | 291.44M | 169.68M | 14.60M | 21.30M |
| Total Debt | 4.41M | 2.69M | 52.83M | 403.00K | 155.00K | 457.00K |
| Total Liabilities | 112.59M | 113.72M | 85.86M | 23.18M | 16.15M | 17.76M |
| Stockholders Equity | 495.80M | 450.12M | 245.11M | 157.51M | 10.35M | 17.79M |
Cash Flow | ||||||
| Free Cash Flow | 105.60M | 46.73M | -69.31M | -24.94M | -20.79M | -27.79M |
| Operating Cash Flow | 105.71M | 46.80M | -69.10M | -24.94M | -20.78M | -27.77M |
| Investing Cash Flow | -186.74M | -201.78M | -225.68M | 0.00 | -13.00K | -22.00K |
| Financing Cash Flow | 132.72M | 137.16M | 213.03M | 180.02M | 14.09M | -128.00K |
Soleno Therapeutics Technical Analysis
Positive
52.78
Price Trends
40.07
Positive
43.19
Positive
55.82
Negative
Market Momentum
4.54
Negative
77.93
Negative
91.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLNO, the sentiment is Positive. The current price of 52.78 is above the 20-day moving average (MA) of 42.80, above the 50-day MA of 40.07, and below the 200-day MA of 55.82, indicating a neutral trend. The MACD of 4.54 indicates Negative momentum. The RSI at 77.93 is Negative, neither overbought nor oversold. The STOCH value of 91.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SLNO.
Soleno Therapeutics Risk Analysis
Soleno Therapeutics disclosed 63 risk factors in its most recent earnings report. Soleno Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soleno Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
SLNO
Soleno Therapeutics
52.95
-23.75
-30.96%
ADMA
ADMA Biologics
8.17
-12.28
-60.05%
KRYS
Krystal Biotech
305.71
166.28
119.26%
Soleno Therapeutics Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Soleno Withdraws EU Application for Prader-Willi Treatment
Negative
Apr 7, 2026
On April 7, 2026, Soleno Therapeutics, Inc. announced that it had voluntarily withdrawn its marketing authorization application in Europe for VIOKAT prolonged-release tablets, known in the U.S. as VYKAT XR, for treating hyperphagia in adults and c...
Business Operations and StrategyM&A Transactions
Soleno Therapeutics to Be Acquired by Neurocrine Biosciences
Positive
Apr 6, 2026
On April 5, 2026, Soleno Therapeutics agreed to be acquired by Neurocrine Biosciences, which will launch a cash tender offer at $53.00 per share, valuing Soleno’s equity at about $2.9 billion and representing a premium of roughly 34% to Sole...
Business Operations and StrategyRegulatory Filings and Compliance
Soleno Therapeutics Updates Bylaws, Tightens Governance Framework
Positive
Mar 16, 2026
On March 16, 2026, Soleno Therapeutics’ Board of Directors approved amended and restated bylaws, acting on recommendations from its Nominating and Corporate Governance Committee. The changes update advance notice requirements for shareholder...
Business Operations and StrategyExecutive/Board Changes
Soleno Therapeutics Announces New Chief Financial Officer Appointment
Positive
Feb 26, 2026
On its February 25, 2026 earnings call, Soleno announced that veteran pharmaceutical finance executive Jennifer Fulk will become chief financial officer on March 2, 2026, succeeding long-time CFO James Mackaness, who plans to retire by the end of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.